Form 4: Corcept CDO Exercises Options, Sells Shares Under 10b5-1 Plan

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a portion of his common stock holdings as part of a pre-arranged trading plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), executed transactions on September 2, 2025.
• Guyer exercised options to acquire 20,000 shares of common stock at an exercise price of $21.65 per share.
• Following the option exercise, he sold 15,594 shares of common stock at a weighted average price of $70.392 per share, with actual sale prices ranging from $69.725 to $70.72.
• An additional 4,406 shares of common stock were sold at a weighted average price of $70.8478 per share, with actual sale prices ranging from $70.725 to $71.08.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Guyer on November 27, 2024.
• After these reported transactions, Guyer beneficially owns 5,487 shares of common stock and 330,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an insider sale can sometimes be viewed negatively, the transactions were pre-planned under a 10b5-1 plan, and the officer realized significant gains from option exercise, which reflects past stock performance. The officer retains substantial option holdings.

Positives

• The exercise of stock options indicates the officer is realizing value from previously granted equity, reflecting past stock price appreciation.
• The sales were executed at significantly higher prices ($70.392 and $70.8478) compared to the option exercise price ($21.65), resulting in substantial personal gains for the officer.
• Transactions were made pursuant to a pre-arranged 10b5-1 plan, which suggests the sales were not based on immediate, non-public information and are part of a planned diversification or liquidity strategy.

Negatives

• An insider selling a significant number of shares, even under a 10b5-1 plan, could be interpreted by some investors as a signal of limited near-term upside or a move towards diversification.
• The net effect of the transactions is a reduction in the officer's direct common stock holdings from 25,487 shares to 5,487 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the sale as a signal, but the 10b5-1 plan mitigates concerns about opportunistic selling. The officer still retains significant option holdings, aligning interests with long-term performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, involving the exercise of stock options and subsequent sale of shares by the Chief Development Officer. While the officer realized substantial gains, the transactions do not provide new fundamental information about the company's operational performance or future prospects. The pre-planned nature mitigates concerns about opportunistic selling. Investors should maintain their current position and look for more substantive corporate updates for investment decisions.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, Share Sale, William Guyer, Chief Development Officer, 10b5-1 Plan